Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 4/20 | 0.31 |
| ▸ | METAP1 | P53582 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736108 | 0.75 | CHRNB2 (0.34) | ACACBALDH1A1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL9357904 | 0.71 | HRH3 (0.45) | SMN1; SMN2MAPK1LMNAHTTHRH3 | |
| SCHEMBL15961737 | 0.71 | HRH3 (0.47) | SMN1; SMN2MAPK1LMNAHTTALDH1A1 | |
| SCHEMBL18921970 | 0.70 | SMN1; SMN2 (0.41) | CYP3A4SMN1; SMN2MAPK1LMNAHTT | |
| SCHEMBL26198819 | 0.70 | SMN1; SMN2 (0.41) | ACACBSMN1; SMN2MAPK1LMNAHTT | |
| SCHEMBL26198820 | 0.70 | SMN1; SMN2 (0.41) | ACACBSMN1; SMN2MAPK1LMNAHTT | |
| SCHEMBL21347466 | 0.69 | LMNA (0.48) | LMNAHRH3 | |
| SCHEMBL11167911 | 0.69 | HRH3 (0.50) | SMN1; SMN2MAPK1HRH3 | |
| SCHEMBL8912054 | 0.69 | SMN1; SMN2 (0.40) | CYP3A4SMN1; SMN2MAPK1LMNAHTT | |
| SCHEMBL22387621 | 0.69 | ACACB (0.43) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | ACACB 1308/4885CYP3A4 415/4885SMN1; SMN2 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.